Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Two Formulations of HR011408 in Healthy Subjects
NCT05147259Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart in diabetes mellitus (DM) (3 cohorts), sponsored by Hengrui. Primary endpoints: Incidence and severity of adverse events, Area under the concentration-time curve and 5 more. Started Nov 2021; status: completed.
02
Drugs
insulin aspart
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05147259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147259.